Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial

Additional Metadata
Persistent URL	doi.org/10.1200/JCO.2013.54.3298, hdl.handle.net/1765/85643
Journal	Journal of Clinical Oncology
Organisation	Erasmus MC Cancer Institute
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Cainap, C., Qin, S., Huang, W.-T., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y.-K., Chen, P.-J., Toh, H.-C., Gorbunova, V., Eskens, F., Qian, J., McKee, M. D., Ricker, J. L., Carlson, D. M.& El-Nowiem, S. (2015). Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial. Journal of Clinical Oncology, 33(2), 172–179.https://doi.org/10.1200/JCO.2013.54.3298

Publication